The main objective of Making Genetics is to identify, develop, implement in clinic and license new diagnostic and prognostic panels combining genetic and epigenetic biomarkers. For this we have the necessary experience for the analysis of the samples, for the bioinformatic studies that come from massive genomic and epigenomic analyzes, and for the biostatistical integration of biomarkers of different biological origins. The proposal of this segment is to become a company that develops personalized medicine by developing for its license a package of original biological determinations (combining different biomarkers) that can address the diagnosis of different diseases in a flexible way.


At the research and development level, we are working on the realization of a predictive algorithm for the severity of inflammatory and autoimmune diseases, based on genetic and epigenetic biomarkers, that allow us to market a service and / or license the technical procedure for its use in routine clinical practice. . Other R & D projects in which we are working are the development and commercialization of pediatric celiac biomarkers together with the Hospital of Navarra.

Meet our R&D


We offer companies and research groups analysis of genomic data (from NGS or microarray technology) through our Department of Bioinformatics together with the biological interpretation of the results. With the possibility of also performing laboratory analyzes.

Learn about our genomic services


At Making Genetics we offer a comprehensive genetic analysis service to companies that have their own commercial network. We offer these companies the development of on-demand genetic panels and the subsequent service during the marketing of custom genetic tests.

Meet our genetic testing service
Adriana Moleres
Adriana MoleresCo-founder and R&D Director
PhD in Biological Sciences with mastery in several areas of knowledge such as Biochemical Genetics, Metabolic Processes, Human Genetics or Human Physiology with more than 7 years of experience in scientific research, has published in scientific journals such as Journal of Pediatrics, FASEB Journal and Pediatric Obesity.
Javier Campion
Javier CampionCo-founder, CEO and Scientific Director
PhD in Biological Sciences with mastery in several areas of knowledge such as Biochemistry, Molecular Biology and Human Genetics with more than 20 years of experience in scientific research (Complutense University, Karolinska Institute of Stockholm and University of Navarra) with more than 10 years of researcher responsible in projects related to nutrigenomics and epigenetics, has published in scientific journals such as Human Molecular Genetics, PLOSone and FASEB Journal.
María Luisa Mansego
María Luisa MansegoBioinformatics Core Director
PhD in Molecular and Evolutionary Genetics with extensive experience in Population Genetics and Bioinformatics and more than 10 years of experience as a scientific researcher working in genotyping, epigenotyping and genetic diagnosis in the Research Center of the University Clinical Hospital of Valencia, the Príncipe Research Center Felipe and the University of Navarra.
Lorena Sánchez
Lorena SánchezProject Manager
PhD in Biology with more than 20 years of experience focused on the study of inflammatory processes from areas such as Immunology, Biochemistry and Molecular Biology (UCM, CSIC and Hosp. Gral. Univ. Gregorio Marañón), has carried out projects of functional genomic research, technology transfer to the pharmaceutical industry and RETICS on rheumatic and inflammatory diseases and published in journals such as Trends in Molecular Medicine, Blood and Journal of Biological Chemistry.

This company has received aid from the expenditure budget of the Ministry of Economy and Competitiveness and co-financed by the European Regional Development Fund for the project RTC-2015-3562-1

This project has received funding from DIGI-B-CUBE voucher framework which has been supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824920.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 877928.